前立腺微小癌における核内DNA量および組織特性に関する研究-細胞イメージ分析装置による核DNA ploiclyの検討-

前列腺微小癌核DNA含量和组织特征的研究-使用细胞图像分析仪对核DNA进行精确检查-

• 批准号: 06771296
• 负责人: 秋山 昭人
• 金额: $ 0.58万
• 依托单位: Tokyo Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Encouragement of Young Scientists (A)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-06771296/
• 关键词: 前立腺癌; ラテント癌; DNA ploicly; イメージサイトメトリー; stage A癌

対象:前立腺ラテント癌64例84病巣。年齢は53〜102歳、平均72.7歳、1前立腺あたり1〜4病巣、平均1.28病巣で、高分化癌47病巣、中分化癌19病巣、低分化癌18病巣であった。結果:60前立腺、、76病巣についてDNA ploidyの測定が可能であった。54病巣(71%)がdiploid、22病巣(29%)がnon-diploidであった。複数の癌病巣を有するものは11前立腺で、うち5前立腺では病巣ごとのploidyが一致せず、ploidy patternのheterogeneityがみられた。60前立腺のうち、20前立腺(33%)で少なくとも1つ以上のnon-diploid病巣が含まれていた。また、高分化癌ではdiploidが88.0%、non-diploidが12.0%であるのに、低分化癌ではそれぞれ27.8%、72.2%と逆転し、中分化癌では丁度その中間の値を示し、高分化癌と中または低分化癌の2者との間において、non-diploid病巣の出現率に有意差が認められた(p<0.001)。76病巣のうち62病巣約82%が500mm^3以下、約半数の39病巣51%は100mm^3以下の微小病巣であった。最小のnon-diploid病巣は高分化癌で25.7mm^3、低分化癌では3.0^3であった。体積100mm^3以下の病巣におけるnon-diploid病変の出現率は15.4%でstageA癌の再発率とほぼ一致した。癌体積の増加と共にnon-diploid病変の出現率が上昇し、体積100mm^3を境に出現率に有意差が認められた(p<0.01)。またクリスタロイドを有する病巣では高分化度で癌体積が小さく、non-diploid cellの出現頻度が低い傾向がみられた。結論:本測定法は、前立腺癌における悪性度や予後判定に際しての既存のパラメーターに加えて、新たな情報をもたらす独立したパラメーターとなる可能性が示唆され、low stageの小さな前立腺癌の予後判定や治療法選択にも十分応用おされるべきものと考えられた。

For example, there were 84 cases of cancer in the anterior standing gland. The average age was 53,102 years, with an average of 72.7 years, 1 anterior gland disease, 4 diseases, 1.28 diseases, 47 diseases of highly differentiated carcinoma, 19 diseases of moderately differentiated carcinoma, and 18 diseases of poorly differentiated carcinoma. Results: 60 years ago, 76 and 60 years ago, the results of DNA ploidy test showed that there might be some disease in the patients. 54 patients (71%) had diploid, 22 patients (29%) had non-diploid infection. The multiplicative cancers include 11 prestanding glands, 5 prestanding glands, ploidy identical tumors and ploidy pattern heterogeneity tumors. 60 prestanding glands (33%) and 20 prestanding glands (33%) were less than 1 in non-diploid 's disease. There were 88.0%, 12.0%, 27.8%, 72.2%, 27.8%, 72.2%, 80.8%, 12.0%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 88.0%, 12.0%, 27.8%, 72.2%, 27.8%, 72.2%, 88.0%, 12.0%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 27.8%, 72.2%, 76 patients with 62 diseases, about 82% with diseases less than 500mm ^ 3, and about half with 39 diseases with diseases less than 51% and 100mm with minimal diseases. The minimum non-diploid disease is 25.7mm ^ 3 for well differentiated cancer and 3.0 ^ 3 for poorly differentiated cancer. Under 100mm ^ 3, the incidence of non-diploid disease is 15.4%. The recurrence rate of stageA cancer is consistent. The incidence of non-diploid disease is higher than that of 100 mm ^ 3, and the incidence of cancer is significantly higher than that of 100 mm. The disease was highly differentiated, the cancer was small, and non-diploid cell showed a low degree of disease. Results: this method and the degree of sex of the anterior adenocarcinoma were used to determine whether the existing cancer was increased, the new cancer was independent, and the possibility of the treatment of the anterior adenocarcinoma was determined by this method, and the possibility of the treatment was determined by the low stage method.

项目成果

秋山 昭人・古里 征国: "前立腺ラテント癌における核内DNA量測定とその意義" 東京医科大学雑誌. 53. (1995)

Akito Akiyama 和 Seikuni Furusato：“前列腺癌中核 DNA 含量的测量及其意义”，东京医科大学学报 53。（1995 年）